HQY vs. ITCI, JAZZ, GMED, CYTK, ELAN, BPMC, RVMD, ENSG, MASI, and PCVX
Should you be buying HealthEquity stock or one of its competitors? The main competitors of HealthEquity include Intra-Cellular Therapies (ITCI), Jazz Pharmaceuticals (JAZZ), Globus Medical (GMED), Cytokinetics (CYTK), Elanco Animal Health (ELAN), Blueprint Medicines (BPMC), Revolution Medicines (RVMD), The Ensign Group (ENSG), Masimo (MASI), and Vaxcyte (PCVX). These companies are all part of the "medical" sector.
Intra-Cellular Therapies (NASDAQ:ITCI) and HealthEquity (NASDAQ:HQY) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, community ranking, valuation, analyst recommendations, dividends, institutional ownership, profitability, media sentiment and earnings.
92.3% of Intra-Cellular Therapies shares are owned by institutional investors. Comparatively, 99.6% of HealthEquity shares are owned by institutional investors. 3.4% of Intra-Cellular Therapies shares are owned by company insiders. Comparatively, 2.7% of HealthEquity shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
In the previous week, Intra-Cellular Therapies had 14 more articles in the media than HealthEquity. MarketBeat recorded 20 mentions for Intra-Cellular Therapies and 6 mentions for HealthEquity. Intra-Cellular Therapies' average media sentiment score of 1.16 beat HealthEquity's score of 0.84 indicating that HealthEquity is being referred to more favorably in the news media.
HealthEquity received 7 more outperform votes than Intra-Cellular Therapies when rated by MarketBeat users. Likewise, 69.24% of users gave HealthEquity an outperform vote while only 67.38% of users gave Intra-Cellular Therapies an outperform vote.
Intra-Cellular Therapies has a beta of 1.01, meaning that its share price is 1% more volatile than the S&P 500. Comparatively, HealthEquity has a beta of 0.55, meaning that its share price is 45% less volatile than the S&P 500.
Intra-Cellular Therapies presently has a consensus price target of $90.17, indicating a potential upside of 33.30%. HealthEquity has a consensus price target of $96.17, indicating a potential upside of 25.69%. Given HealthEquity's higher probable upside, analysts plainly believe Intra-Cellular Therapies is more favorable than HealthEquity.
HealthEquity has higher revenue and earnings than Intra-Cellular Therapies. Intra-Cellular Therapies is trading at a lower price-to-earnings ratio than HealthEquity, indicating that it is currently the more affordable of the two stocks.
HealthEquity has a net margin of 5.57% compared to HealthEquity's net margin of -21.57%. Intra-Cellular Therapies' return on equity of 6.91% beat HealthEquity's return on equity.
Summary
HealthEquity beats Intra-Cellular Therapies on 13 of the 18 factors compared between the two stocks.
Get HealthEquity News Delivered to You Automatically
Sign up to receive the latest news and ratings for HQY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HQY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
HealthEquity Competitors List
Related Companies and Tools
